CAPGAN th Scientific Meeting of Commonwealth Association of Paediatric, Gastroenterology and Nutrition 2-4 October 2015 : New Delhi, India

Similar documents
Outcomes of Liver Transplant for Biliary Atresia: A Ten Year Single Centre Experience

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center

PROGRAMME AT A GLANCE

Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging

Pediatric Liver Tumors and Transplantation. Northwest Regional Pediatric Live Disease Symposium, Seattle WA, April 12, 2008

Liver Cancer: Diagnosis and Treatment Options

Hepatocellular Carcinoma (HCC)

Liver Tumors. Prof. Dr. Ahmed El - Samongy

Hepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center

Hepatocellular Carcinoma: Diagnosis and Management

Hepato-Pancreatico-Biliary Surgery. Dr. Ankur J. Shah. MS, DNB, MNAMS, MRCSEd (UK), FRCS (UK)

Management of HepatoCellular Carcinoma

Tumor incidence varies significantly, depending on geographical location.

Hepatocellular carcinoma in Sri Lanka - where do we stand?

Liver Transplantation for Cholangiocarcinoma. John McCall Division of Surgery Dunedin School of Medicine University of Otago

A) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS

Liver resection for HCC

Hepatocellular Carcinoma. Markus Heim Basel

Ontario s Adult Referral and Listing Criteria for Liver Transplantation

Paediatric Liver Transplant Programme Wits Donald Gordon Medical Centre

Hepatocellular carcinoma

HCC surgical approach: resection and transplantation indications and outcome

TREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD

Life After SVR for Cirrhotic HCV

Worldwide Causes of HCC

British Liver Transplant Group Pathology meeting September Leeds cases

Hepatocellular Carcinoma Surveillance

Interventional Radiology in Liver Cancer. Nakarin Inmutto MD

Radioembolization with Lipiodol for the Treatment of Hepatocellular Carcinoma and Liver Metastases

PEER-REVIEW REPORT CLASSIFICATION LANGUAGE EVALUATION SCIENTIFIC MISCONDUCT CONCLUSION. [ Y] Accept [ ] Grade B: Very good

SEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA

HEALTH SERVICES POLICY & PROCEDURE MANUAL

Transplant Hepatology

Surveillance for Hepatocellular Carcinoma

Worldwide Causes of HCC

Reconsidering Liver Transplantation for HCC in a Era of Organ shortage

NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE LIVER ADVISORY GROUP UPDATE ON THE HCC DOWN-STAGING SERVICE EVALUATION

Hepatocellular Carcinoma: Transplantation, Resection or Ablation?

Approach to a case of Neonatal Cholestasis

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

Liver Directed Therapy for Hepatocellular Carcinoma

LIVER IMAGING TIPS IN VARIOUS MODALITIES. M.Vlychou, MD, PhD Assoc. Professor of Radiology University of Thessaly

Tumor Response to Transcatheter Arterial Chemoembolization in Recurrent Hepatocellular Carcinoma after Living Donor Liver Transplantation

9th Paris Hepatitis Conference

Assessment of Liver Function: Implications for HCC Treatment

Biliary Atresia. Karen F. Murray, MD Professor of Pediatrics Director, Hepatobiliary Program Seattle Children s

Liver Transplantation in Children: Techniques and What the Surgeon Wants to Know from Imaging

Hepatobiliary and Pancreatic Malignancies

TACE: coming of age?

Experience in 1,000 Liver Transplants Under Cyclosporine-Steroid Therapy: A Survival Report

MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC

Liver Cancer. Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine

Supplementary Digital Content

Natural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry

Clinical Significance of Elevated -Fetoprotein in Adults and Children

EASL-EORTC Guidelines

Hepatocellular Carcinoma: Can We Slow the Rising Incidence?

6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare

Surveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice

Kit-Fai Lee, Charing C. N. Chong, Anthony K. W. Fong, Andrew K. Y. Fung, Hon-Ting Lok, Yue-Sun Cheung, John Wong, Paul B. S. Lai

HCC and mass effect. Hepatocellular cancer: what if the AFP is rising but no lesion seen on imaging? What you need to know about AFP.

Pre-treatment alphafeto protein in hepatocellular carcinoma with non-viral aetiology a prospective study

The Egyptian Journal of Hospital Medicine (April 2018) Vol. 71(1), Page

Professor Norbert Bräu

Invited Re vie W. Analytical histopathological diagnosis of small hepatocellular nodules in chronic liver diseases

Liver Cancer And Tumours

HCC: Is it an oncological disease? - No

Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of

All India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology

Adult-to-adult living donor liver transplantation Triumphs and challenges

HCC RADIOLOGIC DIAGNOSIS

HCV TREATMENT PRE- AND POST TRANSPLANTATION

3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice

Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma

Preliminary study of the permeability and safety of covered stents-grafts in pediatric TIPS

Treatment of HCC in real life-chinese perspective

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT

Overall Goals and Objectives for Transplant Hepatology EPAs:

Living donor liver transplantation for hepatocellular carcinoma in Seoul National University

RESEARCH ARTICLE. Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy

Hepatitis B Virus-Related Hepatocellular Carcinoma Presenting at an Advanced Stage: Is it Preventable? Dr Tom Mules NZSG ASM 2018

HCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation

Index. Note: Page numbers of article titles are in boldface type.

Neonatal Cholestasis. What is Cholestasis? Congenital and Pediatric liver diseases 4/26/18

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Selective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma

Unmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim

Liver Transplant Pathology a general view

Jesse Civan, M.D. Medical Director, Jefferson Liver Tumor Center

Liver Transplantation for HCC Which Criteria?

6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration

Learning Objectives. After attending this presentation, participants will be able to:

WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?

간암의다양한병기분류법 : 현재사용중인병기분류를중심으로. Kim, Beom Kyung

Hamad Alsuhaibani,MD KING FAISAL SPECIALIST HOSPITAL &RESEARCH CENTRE.

Guidelines for SIRT in HCC An Evolution

STOP Hepatocellular Carcinoma

Transcription:

CAPGAN2015 14 th Scientific Meeting of Commonwealth Association of Paediatric, Gastroenterology and Nutrition 2-4 October 2015 : New Delhi, India ABSTRACT FORM Abstract Category: Oral Poster 1. GASTROENTEROLOGY 2. HEPATOLOGY 3. NUTRITION Abstract Title: Management of Hepatocellular Carcinoma in Children in Liver Transplantation set-up in India Presenting/Corresponding Author's Name: VIBHOR BORKAR (First name) (Last name) Department: Department of Hepatology. Institute Name Global Hospital, Mumbai and Chennai City Mumbai State: Maharashtra.. Country: India Email Id: vibhor.borkar@gmail.com Co-Author(s): S.No. Full Name Institute Name 1 Naresh Shanmugam 2, Paediatric Hepatology, Gastroenterology and Nutrition 2, Global Hospitals and Health City, Chennai, India 2 Chaya Kelgiri 2, Paediatric Hepatology, Gastroenterology and Nutrition 2, Global Hospitals and Health

3 4 5 6 7 8 Vishal Sachade 1, Mukul Vij 3, Mohamed Rela 4 City, Chennai, India Department of Hepatology 1, Global Hospital Mumbai Department of Pathology 3, Gastroenterology and Nutrition 2, Global Hospitals and Health Department of Liver Transplantation and Hepatobiliary Surgery 4, Global Hospitals and Health City, Chennai, India

Body of Abstract - (Aim/ Methods/ Results/ Conclusions): Introduction/ Aim: Hepatocellular carcinoma (HCC) is a rare tumour in children with incidence of 0.5-1 cases per 1 million per year. We studied the outcome of children with HCC undergoing the orthotropic liver transplantation (OLT) in our centre. Methodology: All children (age 0-18 years) undergoing OLT from 2010 to April 2014 at Pediatric Hepatology, Global Hospital, Chennai, India were reviewed. Standard evaluation was done to investigate the underlying etiology for cirrhosis and HCC. The record of study group was evacuated to study the stage of tumour at presentation, manner of diagnosis, treatment offered and outcome. Children with HCC who presented to out-patient clinic and did not undergo OLT were also evaluated. Results: During the study period 137 children underwent liver transplantation and 26 underwent liver resection at our hospital. HCC was seen in 10 children. Of these 8 underwent OLT. None of the 26 children who had hepatic resection had HCC. Median age of diagnosis of HCC was 60 (range 21 to 168) months. Aetiology of liver disease is as mentioned in the table 1. Of these 10 children with HCC, 8 underwent OLT. HCC was detected by CECT abdomen in all children except two. Three children with HT-1 had multifocal HCC. Immunohistochemistry from the explanted liver confirmed presence of HCC. On histopathological studies, HCC was moderately differentiated in 5 and well-differentiated in 3. Two patients with congenital hepatic fibrosis and cryptogenic cirrhosis had fibro-lamellar variant of HCC. Among those who underwent OLT, seven children survived without recurrence at median follow-up of 12 months (3-23 months). Two children, one with portal vein thrombosis and other with lung metastasis were not offered OLT. None of the child in our study had hepatitis B infection. Conclusion: Multifocal HCC was seen in children with Hereditary Tyrosinaemia. HCC at early stages in children can be cured with liver transplantation. Liver transplantation offered 70 % survival at 12 months in children with HCC. Constant surveillance for HCC is required in children with cirrhosis.

Table 1: Children with hepatocellular carcinoma and their outcome S no Age/Gender Diagnosis Tumor number Largest Size of HCC nodule AFP level (mcg/l) Treatment Follow up 1 11.5yr/Boy Tyrosinemia 2 25 mm - TABC LDLT 23 month 2 5 yr boy Tyrosinemia 1 25mm 28000 TABC LDLT 22 months 3 5 years/ girl Tyrosinemia 2 20 mm NA LDLT 12 months 4 1yr 9months/ Boy PFIC-2 1 25mm 2500 LDLT 12 months 5 9years/ boy Congenital hepatic fibrosis with ARPKD 6 3 years/ girl Biliary atresia 1 60 mm 1.6 LDLT 18 months 1 40 mm - DDLT Died due to primary graft dysfunction 7 9.5 years,/girl PFIC 3 5 20 mm - DDLT 3 months 8 4 years/ boy Tyrosinemia 1 25 mm - No treatment Portal vein thrombosis 9 2 years/ boy PFIC 2 1 30 mm - LDLT 4 months 10 14 years/ girl Cryptogenic cirrhosis 1 100 mm - No treatment Lung metastasis AFP- alpha-feto protein, TACE- Transarterial chemo embolization, LDLT- liver donar liver transplant, DDLTdeath donar liver transplant, PFIC- Progressive familial intrahepatic cholestasis